Literature DB >> 1399942

Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages.

J F Desnottes1, N Diallo.   

Abstract

RP 59500, a new antibacterial agent, is a combination of two compounds, RP 54476 and RP 57669. The uptake of radiolabelled RP 59500, i.e. a mixture containing [14C]-RP 54476 plus RP 57669 or [14C]-RP 57669 plus RP 54476, by J 774 murine macrophages was evaluated by a velocity gradient centrifugation technique. After 120 min, the ratios of cellular to extracellular concentration for RP 54476 and RP 57669 were 34 and 50, respectively. The highest intracellular accumulation of RP 59500 was observed at pH 7-7.5. RP 59500 was found to accumulate less at 4 degrees C than at 37 degrees C. The uptake of RP 59500 by dead macrophages was markedly higher than that by live macrophages. As the extracellular concentration of RP 59500 was increased, the intracellular concentration of each component rose, but not proportionally. The metabolic inhibitors sodium cyanide and potassium fluoride both decreased modestly the entry of RP 57669, but not that of RP 54476, into macrophages. After removal of the extracellular antibiotic, RP 54476 and RP 57669 were released rapidly by the cells until equilibrium was established (45% of the original intracellular RP 59500 remained in the cells after 120 min). The intracellular activity of RP 59500 was assessed by incubating macrophages containing ingested Staphylococcus aureus 209P with the drug (10 x MIC: 2.5 mg/L) at 37 degrees C and determining the number of viable cell-associated bacteria. Approximately 70% of the intracellular bacteria were killed within 120 min of incubation. Thus, RP 59500 attains a high intracellular concentration and is active against intracellular S. aureus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399942     DOI: 10.1093/jac/30.suppl_a.107

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Future prospects and therapeutic potential of streptogramins.

Authors:  E Rubinstein; N Keller
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

4.  Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/ RP 54476).

Authors:  E Bernard; M Bensoussan; F Bensoussan; S Etienne; I Cazenave; E Carsenti-Etesse; Y Le Roux; G Montay; P Dellamonica
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

5.  In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Authors:  P D Walzer; A Ashbaugh; M Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.

Authors:  I Herrera-Insúa; K Jacques-Palaz; B E Murray; R M Rakita
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.